Condition: Cataract · Sponsor: EyePoint Pharmaceuticals, Inc.
A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCUfor the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
This description comes directly from the study's public registry record.
Ramiro Ribeiro, MD, PhD · 833-393-7646 · rribeiro@eyepointpharma.com
Always discuss trial participation with your own doctor first.
| EyePoint Investigational Site | Huntington Beach, California, United States | Recruiting |
| EyePoint Investigational Site | Palo Alto, California, United States | Active Not Recruiting |
| EyePoint Investigative Site | Boston, Massachusetts, United States | Recruiting |
| EyePoint Investigational Site | Jackson, Mississippi, United States | Recruiting |
| EyePoint Investigational Site | Omaha, Nebraska, United States | Recruiting |
| EyePoint Investigational Site | Buffalo, New York, United States | Recruiting |
| EyePoint Investigative Site | New York, New York, United States | Recruiting |
| EyePoint Investigational Site | Rochester, New York, United States | Recruiting |
| EyePoint Investigational Site | Charleston, South Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05191706